Mark Jeffrey De Long Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

Mark Jeffrey De Long is Chief Business & Strat Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 60,395 shares of APLS, which is worth approximately $1.97 Million. The most recent transaction as insider was on Aug 12, 2024, when has been sold 5,201 shares (Common Stock) at a price of $13.85 per share, resulting in proceeds of $72,033. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 60.4K

0% 3M change

16.99% 12M change

Total Value Held $1.97 Million

Mark Jeffrey DeLong Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 12 2024	BUY Exercise of conversion of derivative security	$72,033 $13.85 p/Share	5,201 Added 7.93%	60,395 Common Stock
Mar 18 2024	SELL Open market or private sale	$564,049 $56.9 p/Share	9,913 Reduced 15.34%	54,693 Common Stock
Feb 12 2024	SELL Open market or private sale	$40,458 $67.77 p/Share	597 Reduced 0.92%	64,606 Common Stock
Jan 29 2024	SELL Open market or private sale	$23,539 $64.14 p/Share	367 Reduced 0.56%	65,203 Common Stock
Jan 22 2024	SELL Open market or private sale	$89,960 $65.0 p/Share	1,384 Reduced 2.07%	65,570 Common Stock
Jan 16 2024	SELL Open market or private sale	$108,967 $66.81 p/Share	1,631 Reduced 2.38%	66,954 Common Stock
Jan 16 2024	BUY Grant, award, or other acquisition	-	16,963 Added 19.83%	68,585 Common Stock
Oct 23 2023	SELL Open market or private sale	$6,031 $46.04 p/Share	131 Reduced 0.25%	51,622 Common Stock
Feb 21 2023	SELL Payment of exercise price or tax liability	$25,798 $58.5 p/Share	441 Reduced 0.85%	51,341 Common Stock
Feb 21 2023	BUY Grant, award, or other acquisition	-	5,280 Added 9.25%	51,782 Common Stock
Feb 10 2023	SELL Payment of exercise price or tax liability	$34,310 $51.21 p/Share	670 Reduced 1.42%	46,502 Common Stock
Jan 27 2023	SELL Payment of exercise price or tax liability	$19,366 $52.77 p/Share	367 Reduced 0.77%	47,172 Common Stock
Jan 20 2023	SELL Payment of exercise price or tax liability	$59,805 $52.05 p/Share	1,149 Reduced 2.36%	47,539 Common Stock
Jan 12 2023	BUY Grant, award, or other acquisition	-	19,634 Added 28.74%	48,688 Common Stock
Oct 20 2022	SELL Payment of exercise price or tax liability	$11,368 $58.0 p/Share	196 Reduced 0.67%	29,054 Common Stock
Aug 17 2022	SELL Open market or private sale	$347,500 $69.5 p/Share	5,000 Reduced 14.6%	29,250 Common Stock
Aug 17 2022	BUY Exercise of conversion of derivative security	$77,600 $15.52 p/Share	5,000 Added 12.74%	34,250 Common Stock
Aug 11 2022	SELL Open market or private sale	$335,000 $67.0 p/Share	5,000 Reduced 14.6%	29,250 Common Stock
Aug 11 2022	BUY Exercise of conversion of derivative security	$77,600 $15.52 p/Share	5,000 Added 12.74%	34,250 Common Stock
Aug 08 2022	SELL Open market or private sale	$322,500 $64.5 p/Share	5,000 Reduced 14.6%	29,250 Common Stock
Aug 08 2022	BUY Exercise of conversion of derivative security	$77,600 $15.52 p/Share	5,000 Added 12.74%	34,250 Common Stock
Aug 04 2022	SELL Open market or private sale	$607,500 $60.75 p/Share	10,000 Reduced 25.48%	29,250 Common Stock
Aug 04 2022	BUY Exercise of conversion of derivative security	$155,200 $15.52 p/Share	10,000 Added 20.3%	39,250 Common Stock
Jul 27 2022	SELL Open market or private sale	$285,000 $57.0 p/Share	5,000 Reduced 14.6%	29,250 Common Stock
Jul 27 2022	BUY Exercise of conversion of derivative security	$77,600 $15.52 p/Share	5,000 Added 12.74%	34,250 Common Stock

MJD

Mark Jeffrey De Long

Chief Business & Strat Officer

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Value

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS

Account